Adaptimmune Therapeutics - ADAP Net earnings per share for the last 12 months

Adaptimmune (ADAP) - corporate logo

Adaptimmune is implementing its unique SPEAR technology to reprogram immunity for the treatment of solid tumors. Revenues are based on strategic partnerships, while future growth relies on the launch of drugs for rare types of cancer. The current commercialization phase of breakthrough immuno-oncology methods is driving the price action. The EPS YoY TTM growth value demonstrates business resilience, while 54.80 captures the current state of the parameter.

adaptimmune.com (ADAP): Earnings per share for the last twelve months from 02/11/2024 to 02/20/2024

Financial and market metric breakdowns for Adaptimmune Therapeutics PLC (ADAP)

- current price and projected stock value:
Price Performance Chart Adaptimmune|ADAP - Analyst Consensus Forecast
- issuer market value details:
Market Valuation Adaptimmune Therapeutics PLC|ADAP - Enterprise Value
- book capitalization data:
Net Asset Value per Share Adaptimmune Therapeutics|ADAP - Company Book Value|Market Value to Book Value Ratio adaptimmune.com|ADAP - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Equity Adaptimmune|ADAP - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Adaptimmune|ADAP - Company Aggregate Debts|Debt to Net Assets Adaptimmune Therapeutics PLC|ADAP - Company Long-Term Debts|Short-Term Debt Adaptimmune Therapeutics|Immediate Liquidity Ratio adaptimmune.com
- net income and valuation ratios data:
ADAP - Net Profit|Expected Net Profit Adaptimmune|ADAP - Price to Earnings Ratio|Future Price to Earnings Multiple Adaptimmune|ADAP - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Adaptimmune Therapeutics PLC|ADAP - Operating profit EBITDA|Earnings per share for the trailing year Adaptimmune Therapeutics|ADAP - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months adaptimmune.com|ADAP - Earnings per share growth in current year|Expected earnings per share trend next year Adaptimmune
Fundamental company valuation:ADAP Adaptimmune Therapeutics
Flagship merchandise of adaptimmune.com

The investment attractiveness of Adaptimmune (ADAP) is based on the commercialization of the SPEAR platform and the scaling of sarcoma therapy production. This indicator calculates the annual dynamics of GAAP net income per share, allowing for the exclusion of one-time Non-GAAP adjustments. By analyzing the annual EPS (TTM) growth statistics, an investor can assess the company's real fundamental margin of safety and the risk of divergence between reported earnings and market price.

Competitor analysis for Adaptimmune

Earnings per share for the trailing year LEGN (legendbiotech.com)|SANA: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Autolus Therapeutics PLC|ALLO (Allogene Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Selecta Biosciences Inc. RNAC|Earnings per share for the last twelve months Cellectis S.A. (CLLS)|Earnings per share for the last twelve months CRBU (cariboubio.com)|Earnings per share for the last twelve months Instil Bio TIL|Genenta Science SpA - Earnings per share for the last twelve months|IPSC: Net earnings per share for the last 12 months|Earnings per share for the trailing year JSPR (Jasper Therapeutics)|SNTI: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year CERo Therapeutics Holdings CERO|TCRT (Alaunos Therapeutics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Achilles Tx ACHL|Earnings per share for the last twelve months Cargo Therapeutics (CRGX)|Poseida Corp - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) TSVT (2seventy bio, Inc.)|gracellbio.com (GRCL) - Net earnings per one share for the last twelve months